Skip to main content

Advertisement

Fig. 3 | Breast Cancer Research

Fig. 3

From: Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

Fig. 3

Pharmacokinetic parameters. a Plasma letrozole levels at both dose levels, comparing in each the mean plasma levels in nanograms per milliliter on day 29 versus 1 along the 24-h course. b, c The same as in a for both active nintedanib metabolites BIBF1120-BS and BIBF1202-ZW, respectively. N = 3 in level 1; N = 16 in level 2. Error bars: standard error

Back to article page